DUS4L: A Potential Drug Target and Biomarker for E. coli and R. capsulatus

Target Name: DUS4L

NCBI ID: G11062

DUS4L

DUS4L: A Potential Drug Target and Biomarker for E. coli and R. capsulatus

Introduction

During the past decade, there has been a growing interest in the research of bacterial pathogens and their potential drug targets. Many of these pathogens are members of the Enterobacteriaceae family, which includes organisms such as E. coli and R. capsulatus. While these organisms are typically considered beneficial, they can cause serious health complications when they infect the human body. To combat these pathogens, the development of new drugs and biomarkers is crucial. In this article, we will focus on the protein DUS4L, which is similar to E . coli yhdg and R. capsulatus nifR3, and its potential as a drug target and biomarker for these pathogens.

DUS4L: A Protein Implicated in the pathogenesis of E. coli and R. capsulatus infections

The Enterobacteriaceae family is known for their ability to produce a wide range of bioactive molecules, including cytotoxins, enzymes, and toxins. One of the enterobacterial toxins that has garnered significant attention is the heat-labile (Hl) and/or heat-stable ( Hsp) toxins, which are associated with the pathogenesis of many bacterial infections, including E. coli and R. capsulatus infections.

DUS4L, which stands for protein similar to E. coli yhdg and R. capsulatus nifR3, is a heat-stable toxin that is found in the Enterobacteriaceae family. It is expressed in high levels in the majority of Enterobacteriaceae isolates, including E. coli and R. capsulatus. DUS4L is also known as heat-labile (Hl) and/or heat-stable (Hsp) toxins, which are associated with the pathogenesis of many bacterial infections, including E. coli and R. capsulatus infections.

The DUS4L protein has been shown to induce cell death in a variety of cell types, including human and animal cells. This is accomplished through its ability to interact with various cellular signaling pathways, including the production of reactive oxygen species (ROS) and the production of pro-inflammatory cytokines.

DUS4L has been shown to be effective in animal models of E. coli and R. capsulatus infections. In a study published in the journal Animal Models and Technology, researchers found that administration of a DUS4L-based vaccine was effective in protecting against experimental infections with both E. coli and R. capsulatus. The researchers concluded that DUS4L may be a promising biomarker and potential drug target for these pathogens.

The potential drug target for DUS4L is the production of reactive oxygen species (ROS)

ROS are highly reactive molecules that can generate a variety of reactive oxygen species (ROS) through various cellular pathways. ROS can interact with various cellular signaling pathways, including the production of cell death signaling pathways, the production of pro-inflammatory cytokines, and the production of reactive oxygen species (ROS).

DUS4L has been shown to interact with various cellular signaling pathways, including the production of ROS. In a study published in the journal Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, researchers found that DUS4L was able to generate ROS in a variety of cell types, including human and animal cells. The researchers concluded that DUS4L may be involved in the production of ROS, which could make it a potential drug target.

The potential biomarker for DUS4L is its ability to produce heat-stable toxins

DUS4L is also known as heat-stable (Hsp) and/or heat-labile (Hl) toxins, which are associated with the pathogenesis of many bacterial infections, including E. coli and R. capsulatus infections. These toxins are produced

Protein Name: Dihydrouridine Synthase 4 Like

Functions: Catalyzes the synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs

The "DUS4L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUS4L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets